\-\ Texto\\:\\ \ \(0\)\
\-\ mental\\ status\\ changes\\,\\ aphasia\\.\ \(0\)\
\-\ the\\ patient\\ received\\ a\\ 14\\ day\\ course\\ of\\ iv\\ acyclovir\\.\\ \\ he\\ remained\\ aphasic\\ but\\ otherwise\\ responded\\ well\\.\ \(0\)\
\-\ bilateral\\ temporal\\ lobe\\ involvement\\ \\(l\\>r\\)\\ with\\ low\\ attenuation\\ on\\ non\\-contrast\\ ct\\,\\ enhancement\\ with\\ gadolinium\\ on\\ t1\\,\\ t2\\ hyper\\-intensity\\ and\\ restricted\\ diffusion\\ consistent\\ with\\ edema\\.\ \(0\)\
\-\ hsv\\ encephalitis\ \(0\)\
\-\ hsv\\ encephalitis\ \(0\)\
\-\ vzv\\ encephalitis\ \(0\)\
\-\ hhv\\-6\\ encephalitis\ \(0\)\
\-\ ebv\\ encephalitis\ \(0\)\
\-\ vasculitis\ \(67\)\
\-\ syphilis\ \(15\)\
\-\ tuberculous\\ meningitis\ \(2\)\
\-\ wnv\ \(0\)\
\-\ 21\\ y\\/o\\ soldier\\ deployed\\ to\\ iraq\\.\\ \\ found\\ down\\ in\\ barracks\\ three\\ days\\ after\\ being\\ treated\\ for\\ non\\-specific\\ viral\\ illness\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ encephalitis\\:\\ 0\\.5538042235464885\ \(0\)\
\-\ hsv\\:\\ 0\\.27504376051325835\ \(0\)\
\-\ vzv\\:\\ 0\\.1781246829695035\ \(0\)\
\-\ aphasic\\:\\ 0\\.17020764396576663\ \(0\)\
\-\ wnv\\:\\ 0\\.17020764396576663\ \(0\)\
\-\ barracks\\:\\ 0\\.1645904153985454\ \(0\)\
\-\ acyclovir\\:\\ 0\\.1431391088238504\ \(0\)\
\-\ iraq\\:\\ 0\\.14157620926493927\ \(0\)\
\-\ responded\\:\\ 0\\.14012919028772966\ \(0\)\
\-\ ebv\\:\\ 0\\.13878204784903603\ \(0\)\
\-\ tuberculous\\:\\ 0\\.13316481928181484\ \(0\)\
\-\ syphilis\\:\\ 0\\.13043585265337937\ \(0\)\
\-\ deployed\\:\\ 0\\.12880775830700048\ \(0\)\
\-\ aphasia\\:\\ 0\\.12398761268567106\ \(0\)\
\-\ soldier\\:\\ 0\\.12398761268567106\ \(0\)\
\-\ illness\\:\\ 0\\.11204168548596152\ \(0\)\
\-\ remained\\:\\ 0\\.11015061314820868\ \(0\)\
\-\ meningitis\\:\\ 0\\.10491253864390027\ \(0\)\
\-\ vasculitis\\:\\ 0\\.10336731751146312\ \(0\)\
\-\ viral\\:\\ 0\\.10274076683475078\ \(0\)\
\-\ mental\\:\\ 0\\.09707222202062954\ \(0\)\
\-\ received\\:\\ 0\\.09691907754375485\ \(0\)\
\-\ restricted\\:\\ 0\\.09573533204775651\ \(0\)\
\-\ diffusion\\:\\ 0\\.09382218416134733\ \(0\)\
\-\ gadolinium\\:\\ 0\\.09280762761502008\ \(0\)\
\-\ down\\:\\ 0\\.09048037399660568\ \(0\)\
\-\ 21\\:\\ 0\\.08900203854001792\ \(0\)\
\-\ temporal\\:\\ 0\\.08556106892908916\ \(0\)\
\-\ attenuation\\:\\ 0\\.08522295103088909\ \(0\)\
\-\ 14\\:\\ 0\\.08315732210983726\ \(0\)\
\-\ course\\:\\ 0\\.08227298286641571\ \(0\)\
\-\ involvement\\:\\ 0\\.08061608936923093\ \(0\)\
\-\ iv\\:\\ 0\\.07958478324374518\ \(0\)\
\-\ otherwise\\:\\ 0\\.07939733392534137\ \(0\)\
\-\ status\\:\\ 0\\.07772948223113321\ \(0\)\
\-\ being\\:\\ 0\\.0776156287265897\ \(0\)\
\-\ three\\:\\ 0\\.0747685620160993\ \(0\)\
\-\ found\\:\\ 0\\.07206948076464627\ \(0\)\
\-\ day\\:\\ 0\\.07094866905840558\ \(0\)\
\-\ days\\:\\ 0\\.0705098681042711\ \(0\)\
\-\ t1\\:\\ 0\\.06939818655600621\ \(0\)\
\-\ treated\\:\\ 0\\.06936095905053156\ \(0\)\
\-\ changes\\:\\ 0\\.06731486931316935\ \(0\)\
\-\ on\\:\\ 0\\.06727878474166182\ \(0\)\
\-\ edema\\:\\ 0\\.0664309008331251\ \(0\)\
\-\ he\\:\\ 0\\.06595656607353931\ \(0\)\
\-\ with\\:\\ 0\\.06543019089769722\ \(0\)\
\-\ lobe\\:\\ 0\\.06436724943566187\ \(0\)\
\-\ enhancement\\:\\ 0\\.06410976235439414\ \(0\)\
\-\ t2\\:\\ 0\\.06408136115563158\ \(0\)\
\-\ low\\:\\ 0\\.06391181606108802\ \(0\)\
\-\ consistent\\:\\ 0\\.060394086488691635\ \(0\)\
\-\ bilateral\\:\\ 0\\.0598610042680818\ \(0\)\
\-\ but\\:\\ 0\\.05507876384692287\ \(0\)\
\-\ after\\:\\ 0\\.05403342125231863\ \(0\)\
\-\ well\\:\\ 0\\.053931900292041424\ \(0\)\
\-\ ct\\:\\ 0\\.04240432003551131\ \(0\)\
\-\ patient\\:\\ 0\\.03622709859050864\ \(0\)\
\-\ for\\:\\ 0\\.033759146323066216\ \(0\)\
\-\ to\\:\\ 0\\.027845377670780016\ \(0\)\
\-\ in\\:\\ 0\\.027708322779554193\ \(0\)\
\-\ and\\:\\ 0\\.02301580638368429\ \(0\)\
\-\ the\\:\\ 0\\.022224821878415426\ \(0\)\
\-\ of\\:\\ 0\\.021797039906415603\ \(0\)\
